Pages that link to "Q34984079"
Jump to navigation
Jump to search
The following pages link to Optimal therapy of hepatitis C. (Q34984079):
Displaying 50 items.
- Hepatitis C: a review for primary care physicians (Q22306040) (← links)
- Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity (Q24300867) (← links)
- Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus (Q24658111) (← links)
- Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro (Q27472610) (← links)
- Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system (Q27472717) (← links)
- Amantadine therapy for chronic hepatitis C (Q27473307) (← links)
- Managing Occupational Risks for Hepatitis C Transmission in the Health Care Setting (Q27477626) (← links)
- Monitoring Response to Antiviral Therapy for Patients with Chronic Hepatitis C Virus Infection by a Core-Antigen Assay (Q27478083) (← links)
- Replicative Homeostasis III: implications for antiviral therapy and mechanisms of response and non-response (Q27478215) (← links)
- Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1 (Q27478313) (← links)
- Analysis of Hepatitis C Virus Superinfection Exclusion by Using Novel Fluorochrome Gene-Tagged Viral Genomes (Q27480348) (← links)
- Binding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase Inhibitors (Q27480926) (← links)
- Cell Culture Adaptation of Hepatitis C Virus and In Vivo Viability of an Adapted Variant (Q27485033) (← links)
- Cytopathic and Noncytopathic Interferon Responses in Cells Expressing Hepatitis C Virus Subgenomic Replicons (Q27485424) (← links)
- Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase Inhibitors (Q27486249) (← links)
- Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation (Q27486836) (← links)
- Hepatitis C virus replicons: dinosaurs still in business? (Q27488905) (← links)
- Hepatitis C Virus entry: the early steps in the viral replication cycle (Q27489242) (← links)
- Hepatitis C: a clinical review (Q27490788) (← links)
- The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China (Q28550281) (← links)
- IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy (Q29614896) (← links)
- Hepatitis C treatment: where are we now? (Q30378509) (← links)
- Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. (Q30767073) (← links)
- Anti-Helicobacter pylori seropositivity: influence on severity and treatment response in patients with chronic hepatitis C. (Q33373813) (← links)
- Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study (Q33374135) (← links)
- Phlebotomy improves histology in chronic hepatitis C males with mild iron overload. (Q33629438) (← links)
- Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations (Q33866448) (← links)
- PCBP2 enhances the antiviral activity of IFN-α against HCV by stabilizing the mRNA of STAT1 and STAT2. (Q34055577) (← links)
- Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients (Q34103218) (← links)
- Kinetic and dynamic computational model-based characterization of new proteins in mice: application to interferon alpha linked to apolipoprotein A-I. (Q34359523) (← links)
- A cell culture adapted HCV JFH1 variant that increases viral titers and permits the production of high titer infectious chimeric reporter viruses (Q34427768) (← links)
- Cell penetrable humanized-VH/V(H)H that inhibit RNA dependent RNA polymerase (NS5B) of HCV. (Q34474314) (← links)
- The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. (Q34588247) (← links)
- New combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0. (Q34605687) (← links)
- Envelope 2 protein phosphorylation sites S75 & 277 of hepatitis C virus genotype 1a and interferon resistance: a sequence alignment approach (Q34615960) (← links)
- Protein kinase expression as a predictive factor for interferon response in chronic hepatitis C patients (Q34961241) (← links)
- Inhibition of full length hepatitis C virus particles of 1a genotype through small interference RNA (Q34980601) (← links)
- Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine (Q35004972) (← links)
- Collaboration between Hepatologists and Primary Care Physicians in Treating Patients with Chronic Hepatitis C. (Q35022767) (← links)
- Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection (Q35136312) (← links)
- Social support and clinical outcomes during antiviral therapy for chronic hepatitis C (Q35393471) (← links)
- Providing treatment for hepatitis C in an Australian district centre (Q35518843) (← links)
- Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. (Q35579382) (← links)
- Management of chronic hepatitis C virus infection: a new era of disease control (Q35823410) (← links)
- Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis (Q36015711) (← links)
- Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy (Q36184075) (← links)
- Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada (Q36272393) (← links)
- Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone (Q36276664) (← links)
- A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C. (Q36306694) (← links)
- Hepatocellular carcinoma: therapy and prevention (Q36377949) (← links)